UNSPSC 51281654: Kanamycin a sulfate

This classification denotes an aminoglycoside antibiotic with the molecular formula C18H36N4O11.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J80EX28SMQ, chemically known as d-streptamine, o-3-amino-3-deoxy-.alpha.-d-glucopyranosyl(1->6)-o-(6-amino-6-deoxy-.alpha.-d-glucopyranosyl(1->4))-2-deoxy-, sulfate (1:1) (salt), but more generally known as kanamycin a sulfate, which bears US NIH Compound Identifier 32943.

UNSPSC 51281654 Kanamycin a sulfate is a Commodity code under which state and local procurement records show minimal direct activity aligned with the antibiotic's nominal scope. The recent opportunities tagged to this code—including Seminole County's procurement of naloxone and drug deactivation systems, the City of Tampa's purchase of emergency medical and first aid supplies, Texas Health and Human Services' Request for Information on direct-to-manufacturer prescription programs, and Minnesota's multistate cooperative purchasing effort for generic pharmaceuticals and OTC products—do not represent solicitations for kanamycin a sulfate specifically. These opportunities instead reflect broader categories of pharmaceutical procurement, emergency medical supplies, and state-administered drug programs where the code assignment appears to be a tagging mismatch rather than evidence of actual kanamycin purchasing activity.

The issuing bodies engaging in recent pharmaceutical and medical supply procurement under related codes include county health departments (Seminole County, Florida), municipal fire and rescue divisions (City of Tampa), state health agencies (Texas HHS Commission), and multistate cooperative purchasing consortiums (Minnesota MMCAP, serving participating jurisdictions including Oregon). The geographic spread spans Florida, Texas, Minnesota, and Oregon across the most recent opportunities posted between March and June 2026. However, the absence of direct kanamycin solicitations in these records, combined with the evident mismatch between the code's antibiotic scope and the naloxone, medical device, and general pharmaceutical purchasing being conducted, indicates the code shows little relevant recent activity. State and local procurement professionals tracking kanamycin a sulfate sourcing should monitor pharmaceutical cooperative purchasing vehicles and state health department requests for proposal directly rather than relying on this code's current posting activity.